Muutke küpsiste eelistusi

Pharmaceutical Residues in Freshwater: Hazards and Policy Responses [Pehme köide]

  • Formaat: Paperback / softback, 136 pages, kõrgus x laius x paksus: 234x156x18 mm
  • Sari: OECD Report Series
  • Ilmumisaeg: 15-Jul-2020
  • Kirjastus: IWA Publishing
  • ISBN-10: 1789061814
  • ISBN-13: 9781789061819
Teised raamatud teemal:
  • Formaat: Paperback / softback, 136 pages, kõrgus x laius x paksus: 234x156x18 mm
  • Sari: OECD Report Series
  • Ilmumisaeg: 15-Jul-2020
  • Kirjastus: IWA Publishing
  • ISBN-10: 1789061814
  • ISBN-13: 9781789061819
Teised raamatud teemal:
This report calls for a better understanding of the effects of pharmaceutical residues in the environment, greater international collaboration and accountability distribution, and policy actions to prevent and remedy emerging concerns. Laboratory and field tests show traces of oral contraceptives causing the feminisation of fish and amphibians, and residues of psychiatric drugs altering fish behaviour. Antimicrobial resistance, linked to the overuse of antibiotics, has rapidly escalated into a global health crisis. Unless adequate measures are taken to manage the risks, pharmaceutical residues will increasingly be released into the environment as ageing populations, advances in healthcare, and intensification of meat and fish production spur the demand for pharmaceuticals worldwide. The report outlines a collective, life cycle approach to managing pharmaceuticals in the environment. A policy mix of source directed, use orientated and end of pipe measures, involving several policy sectors, can help to improve health and protect the environment.
Foreword 3(2)
Acknowledgements 5(5)
Abbreviations 10(2)
Executive Summary 12(5)
Advances in monitoring can help close the knowledge gap and support policy responses
12(1)
Moving towards proactive policy action to curb pharmaceutical pollution
13(1)
OECD Policy Recommendations on addressing pharmaceutical residues in freshwater
14(1)
Cross-cutting recommendations
14(1)
Source-directed recommendations. Pharmaceutical life cycle stages: design, marketing authorisation, manufacturing, post-authorisation
15(1)
Use-orientated recommendations. Pharmaceutical life cycle stages: Prescription and use
15(1)
End-of-pipe recommendations. Pharmaceutical life cycle stages: collection and disposal, and wastewater treatment and reuse
15(2)
1 Defining the challenge of managing pharmaceuticals in water
17(40)
1.1 Key messages
18(1)
1.2 Introduction
18(2)
1.3 Origins, entry-pathways, sinks and concentration patterns of pharmaceuticals in the environment
20(11)
1.4 Effects of pharmaceuticals in the environment on human and freshwater ecosystem health
31(26)
References
40(16)
Notes
56(1)
2 Opportunities to build a policy-relevant knowledge base
57(27)
2.1 Key messages
58(1)
2.2 Environmental risk assessment and authorisation of pharmaceuticals
58(6)
2.3 Existing frameworks for monitoring pharmaceuticals in water
64(4)
2.4 Advances in water quality monitoring and potential benefits for risk assessments and water quality policy making
68(7)
2.5 The added value of system modelling
75(9)
References
77(6)
Notes
83(1)
3 Emerging policy instruments for the control of pharmaceuticals in water
84(33)
3.1 Key messages
85(1)
3.2 Introduction
85(1)
3.3 Source-directed approaches
85(6)
3.4 Use-orientated approaches
91(7)
3.5 End-of-pipe measures
98(19)
References
110(7)
4 Recommendations for the management of pharmaceuticals in freshwater
117(14)
4.1 Key messages: A life cycle, multi-sector approach to managing pharmaceutical residues in freshwater
118(1)
4.2 A policy toolbox for a life cycle, multi-sector approach
118(2)
4.3 The interlinkages between freshwater, pharmaceutical, and human and animal health policies
120(6)
4.4 A life cycle, multi-sector approach: Experience from selected OECD countries
126(5)
References
131(2)
Notes 133(1)
Glossary 134